Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Inhibition of Mutated, Activated BRAF in Metastatic MelanomaKeith T. Flaherty, Paul B. Chapman, Igor Puzanov et al.|New England Journal of Medicine|2010Cited by 3.5k
Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B. Johnson, Javid J. Moslehi, Justin M. Balko et al.|New England Journal of Medicine|2016Cited by 2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L. Topalian, F. Stephen Hodi, Mario Sznol et al.|Journal of Clinical Oncology|2014Cited by 2.2k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Peter Hirth et al.|Nature|2010Cited by 1.8k